CorFlow Therapeutics is incorporated in Baar, Switzerland, and closed it’s Seed financing round in September 2016 and completed the first closing of the Seed+ round in October 2017. Both rounds were lead by leading cardiovascular seed investors who over decades have successfully invested in innovative medical device companies such as CoreValve and CardiAQ. The rounds were also supported by interventional cardiology key opinion leaders such as Jacques Séguin, Jean-Claude Laborde and Arshad Quadri (“Q”). Finally, the seed rounds were funded by leading cardiovascular device distributors in Europe, Japan, Latin-America and China.

The company plans successive investment rounds and invites investors who want to support an innovative technology to diagnose and treat microvascular obstruction to participate in these upcoming rounds.

Feel free to contact CorFlow’s CEO, Jon H. Hoem,

+41 79 606 2 902

for further details on the upcoming financing rounds.